http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-106543-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c2ff03c5af3feb781c1c80c5efa291 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-179 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 |
| filingDate | 2016-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-106543-A1 |
| titleOfInvention | NTN1 NEUTRALIZING AGENT COMBINATION THERAPY WITH DRUGS THAT INHIBIT EPIGENTICAL CONTROL |
| abstract | The pharmaceutical or anticancer composition for the treatment of a cancer that has a loss dependent on DNA methylation, on the expression of NTN1, UNC5H or DAPK1. It also refers to a method of treating such types of cancer. The composition comprises an epigenetic drug and an NTN1 neutralizing agent or a vector capable of expressing an NTN1 neutralizing agent in vivo, in a pharmaceutically acceptable carrier or vehicle. The NTN1 neutralizing agent, such as an antibody that binds to netrin-1 or a netrin-1 receptor, promotes apoptosis induced by netrin-1 receptors. The epigenetic drug can be a DNA methyltransferase inhibitor or an HDAC inhibitor. Claim 1: A pharmaceutical composition comprising an epigenetic drug selected from a DNA methylation inhibitor and an inhibitor having histone inhibitory activity, and an NTN1 neutralizing agent or a vector capable of expressing an NTN1 neutralizing agent in vivo, in a pharmaceutically acceptable carrier or vehicle. Claim 7: The composition of claim 6, wherein the DNA methyltransferase inhibitor is selected from the group consisting of azacitidine; decitabine; zebularin; 5,6-dihydro-5-azacitidine; 5-fluoro-2’-deoxycytidine; NPEOC-DAC; CP-4200; and decitabine-p-deoxyguanosine (SGl-110), procainamide, procaine, hydralazine, (-) - epigallocatequin-3-gallate (EGCG), N-phthalyl-1-tryptophan (RG108) and SGI-1027. Claim 9: The composition of claim 8, wherein the HDAC inhibitor is a hydroxamic acid or a cyclic peptide. Claim 14: The composition for use according to claim 11, 12 or 13, which comprises the epigenetic drug and the NTN1 neutralizing agent or vector capable of expressing an NTN1 neutralizing agent in vivo, for simultaneous, separate administration or sequential to a patient. |
| priorityDate | 2015-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.